ACT-335827 (CAS 1354039-86-3)
Alternate Names:
(R,Z)-2-((S)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-isopropyl-2-phenylacetimidic acid
CAS Number:
1354039-86-3
Molecular Weight:
518.64
Molecular Formula:
C31H38N2O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
ACT-335827 (CAS 1354039-86-3) References
- The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. | Steiner, MA., et al. 2013. Front Pharmacol. 4: 165. PMID: 24416020
- Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. | Beig, MI., et al. 2015. Neuropharmacology. 89: 146-56. PMID: 25239810
- A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. | Bonaventure, P., et al. 2015. J Pharmacol Exp Ther. 352: 590-601. PMID: 25583879
- The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. | Perrey, DA., et al. 2015. Bioorg Med Chem. 23: 5709-24. PMID: 26216017
- Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities. | Andrews, SP., et al. 2016. Curr Top Med Chem. 16: 3438-3469. PMID: 26416477
- An alerting structure: human orexin receptor 1. | Wacker, D. and Roth, BL. 2016. Nat Struct Mol Biol. 23: 265-6. PMID: 27045444
- Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide. | Futamura, A., et al. 2017. Bioorg Med Chem. 25: 5203-5215. PMID: 28807572
- Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793. | Préville, C., et al. 2020. ACS Med Chem Lett. 11: 2002-2009. PMID: 33062185
- Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats. | Bergamini, G., et al. 2024. J Psychopharmacol. 38: 305-308. PMID: 38327032
- Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder. | Steiner, MA., et al. 2024. Int J Eat Disord.. PMID: 38456603
Inhibitor of:
QRFP.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ACT-335827, 10 mg | sc-507324 | 10 mg | $1280.00 |